<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00791011</url>
  </required_header>
  <id_info>
    <org_study_id>20060340</org_study_id>
    <nct_id>NCT00791011</nct_id>
  </id_info>
  <brief_title>Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat</brief_title>
  <official_title>A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is a multi-center, phase 1b study of AMG 655 in combination with bortezomib or
      vorinostat in subjects with relapsed or refractory low grade lymphoma, mantle cell lymphoma,
      diffuse large cell lymphoma, and Hodgkin's disease.

      Part 1 is an open-label, dose-escalation phase (3+3 design) to determine the safety,
      tolerability and maximum tolerated dose of AMG 655 in combination with bortezomib or
      vorinostat. Subjects will be enrolled into one of two arms based on investigator selection
      (either the bortezomib + AMG 655 arm or vorinostat + AMG 655 arm).

      Part 2 of the study is a dose expansion phase that will commence after dose selection of AMG
      655 in combination with bortezomib in Part 1. In Part 2, subjects (n = 20) with mantle cell
      lymphoma will be given AMG 655 in combination with bortezomib. The dose of AMG 655 used in
      combination with bortezomib will be based on safety and pharmacokinetic information obtained
      from Part 1 as well as from ongoing AMG 655 trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Safety: Subject incidence of treatment emergent adverse events, Dose Limiting Toxicities, the severity of adverse events and clinically significant changes in safety laboratory tests, physical examinations, or vital signs.</measure>
    <time_frame>Length of Study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Objective response rate of AMG 655 Therapy as determined by using IWG criteria at the dose selected in Part 1, in combination with Bortezomib in subjects with mantle cell lymphoma</measure>
    <time_frame>Length of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall survival (OS).</measure>
    <time_frame>Length of study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression-Free Survival (PFS).</measure>
    <time_frame>Length of treatment phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: PK parameters for AMG 655 on a 3 week dosing schedule.</measure>
    <time_frame>Treatment and follow up phase of study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Subject incidence of anti-AMG 655 antibody formation.</measure>
    <time_frame>Treatment and follow up phase of study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of response.</measure>
    <time_frame>Length of treatment phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Subject incidence of anti-AMG 655 antibody formation.</measure>
    <time_frame>Treatment and follow up phase of study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Best tumor response, objective response rate and duration of response.</measure>
    <time_frame>Length of treatment phase.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum tolerated dose of AMG 655 administered with bortezomib or vorinostat, if reached.</measure>
    <time_frame>First 21 days of treatment for each cohort.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: PK parameters for AMG 655 on a 3 week dosing schedule.</measure>
    <time_frame>Treatment and follow up phase of study.</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Low Grade Lymphoma</condition>
  <condition>Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Diffuse Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 (intermediate dose) with Vorinostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 (low dose) with Bortezomib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 (low dose) with vorinostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 (high dose) with Bortezomib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 (high dose) with Vorinostat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 (intermediate dose) with Bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 655</intervention_name>
    <description>AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>SAHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>A dipeptide boronic acid analogue with antineoplastic activity.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Subjects must have a pathologically confirmed diagnosis of lymphoma that is
             relapsed or refractory to standard treatment or for which no curative therapy is
             available. Lymphoma subtypes that are eligible for enrollment include low grade
             lymphoma, mantle cell lymphoma, diffuse large cell lymphoma, and Hodgkin's disease.

          -  Part 2: Subjects must have relapsed or refractory mantle cell lymphoma with at least
             one objective measurable disease site (ie, measurable in at least 2 perpendicular
             parameters). Subjects must have had at least one prior antineoplastic therapy, up to a
             maximum of 3. At least one therapy must have included an anthracycline. Subjects must
             have had documented relapse or progression following the last therapy (ie, most recent
             therapy given prior to enrollment). An abnormal PET scan will not constitute evaluable
             disease, unless verified by CT or MRI scan).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate hematologic, renal, hepatic and coagulation function

        Exclusion Criteria:

          -  A history of other malignancies, except: adequately treated non-melanoma skin cancer,
             curatively treated in-situ cancer of the cervix, or other solid tumors curatively
             treated with no evidence of disease for â‰¥ 5 years.

          -  A history of allogeneic stem-cell transplantation

          -  Primary central nervous system (CNS) tumors including primary CNS lymphoma

          -  Central nervous system involvement by lymphoma

          -  Myocardial infarction within 6 months before enrollment, symptomatic congestive heart
             failure (New York Heart Association &gt;class II), unstable angina, or unstable cardiac
             arrhythmia requiring medication

          -  Vorinostat cohorts only: History of significant GI surgery or disease, which would
             impair intestinal absorption

          -  Vorinostat cohorts only: Active peptic ulcer disease

          -  Prior exposure to AMG 655 or other investigational TRAIL receptor agonists is not
             permitted

          -  Prior treatment with bortezomib or vorinostat is not permitted for subjects enrolling
             in the bortezomib and vorinostat cohorts, respectively

          -  Major surgery within 28 days before the first dose of AMG 655
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Younes A, Sokol L, Ribeiro de Oliveira M, Popplewell L, Romaguera JE, Copeland A, Sabin T, Hsu CP, Pan Y, Gorski K, Hwang Y, Wong S, Beaupre D, Kirschbaum MH.A Phase 1b Study Simultaneously Evaluating Two Novel Conatumumab-Based Combinations in Patients With Relapsed or Refractory Lymphoma.Journal-001239;</citation>
  </reference>
  <reference>
    <citation>Younes A, Sokol L, Ribeiro de Oliveira M, Popplewell L, Romaguera JE, Copeland A, Sabin T, Hsu CP, Pan Y, Gorski K, Hwang Y, Wong S, Beaupre D, Kirschbaum MH.A Phase 1b Study Simultaneously Evaluating Two Novel Conatumumab-Based Combinations in Patients With Relapsed or Refractory Lymphoma.Journal-004521;</citation>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2008</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>AMG 655</keyword>
  <keyword>Trail receptor</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Vorinostat</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>SAHA</keyword>
  <keyword>Velcade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

